🔗 Share this article The Global Health Body Sounds Concern Over Severe Scarcity of Obesity Injections Under one in 10 individuals who could benefit from obesity jabs including Wegovy are able to get them, warns the World Health Organization as it publishes its initial recommendations on the therapies. Given over a billion individuals worldwide now living with obesity, it is urging increased and just availability to these injectable treatments. Based on projections, more than two billion could be living with obesity by 2030 without intervention. "Our latest guidelines acknowledges that obesity is a lifelong illness that can be addressed with holistic and ongoing support," remarked its chief Tedros Adhanom Ghebreyesus. High costs, constrained manufacturing, and supply-chain constraints are major hurdles to broad access to the injections that can assist patients in reducing substantial body mass, says the body. GLP-1 Therapy Supply Crisis Even under the present best projected scenario, the production of such drugs could only cover around 100 million people – under 10% of those who need them, as stated by the WHO. The advice encourages countries and companies to expand availability, through measures such as patent sharing. The intellectual property rights on semaglutide – the main ingredient of a leading brand – is scheduled to end in several nations in 2026. How Obesity Drugs Function The injections replicate a body's own hormone to delay gastric emptying, suppress the appetite and increase the sense of being full so people consume fewer calories. Individuals typically begin shedding pounds in the initial weeks of beginning the once-weekly jabs. Evidence suggests users may regain a significant portion after a year of halting the drug, because their usual appetite come back. Being above a healthy weight increases your likelihood for experiencing medical conditions, like diabetes, cardiovascular issues, brain attack, and certain cancers. Excess weight impacts people in all nations and was responsible for millions of deaths worldwide in 2024, per the health agency.
Under one in 10 individuals who could benefit from obesity jabs including Wegovy are able to get them, warns the World Health Organization as it publishes its initial recommendations on the therapies. Given over a billion individuals worldwide now living with obesity, it is urging increased and just availability to these injectable treatments. Based on projections, more than two billion could be living with obesity by 2030 without intervention. "Our latest guidelines acknowledges that obesity is a lifelong illness that can be addressed with holistic and ongoing support," remarked its chief Tedros Adhanom Ghebreyesus. High costs, constrained manufacturing, and supply-chain constraints are major hurdles to broad access to the injections that can assist patients in reducing substantial body mass, says the body. GLP-1 Therapy Supply Crisis Even under the present best projected scenario, the production of such drugs could only cover around 100 million people – under 10% of those who need them, as stated by the WHO. The advice encourages countries and companies to expand availability, through measures such as patent sharing. The intellectual property rights on semaglutide – the main ingredient of a leading brand – is scheduled to end in several nations in 2026. How Obesity Drugs Function The injections replicate a body's own hormone to delay gastric emptying, suppress the appetite and increase the sense of being full so people consume fewer calories. Individuals typically begin shedding pounds in the initial weeks of beginning the once-weekly jabs. Evidence suggests users may regain a significant portion after a year of halting the drug, because their usual appetite come back. Being above a healthy weight increases your likelihood for experiencing medical conditions, like diabetes, cardiovascular issues, brain attack, and certain cancers. Excess weight impacts people in all nations and was responsible for millions of deaths worldwide in 2024, per the health agency.